跳至主要内容
临床试验/NCT02738463
NCT02738463Unknown不适用

Role of Maternal Serum Ferritin in the Prediction of Low Neonatal Birth Weight

Ain Shams Maternity Hospital2 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
64
试验地点
2
主要终点
maternal serum ferritin (microg/L)

研究概览

简要总结

Intrauterine growth restriction ( IUGR )is defined as fetal growth slower than the normal growth potential of a specific fetus because of genetic or environmental factors. Recently several studies have highlighted the role of many biomolecules as markers for IUGR. Measurement of maternal serum ferritin has also been used as a predictive marker for increased risk of IUGR. Iron deficiency has its known deleterious effect in pregnancy but iron loading may be associated with oxidative damage to cells and tissues. It has been shown in various studies that lower level of transferritin receptor expression in placenta is associated with preeclampsia and IUGR. This can lead to decrease extraction of iron by placenta from maternal serum leading to increase maternal serum ferritin. This fetal iron deficiency leads to increase in fetal corticotropins and fetal cortisol, causing inhibition of fetal growth

详细描述

Intrauterine growth restriction (IUGR) is defined as fetal growth slower than the normal growth potential of a specific fetus because of genetic or environmental factors. IUGR is associated with a high incidence of perinatal morbidity and mortality. IUGR neonates have a greater risk of hypoxic ischemic encephalopathy, intraventricular hemorrhage and necrotizing enterocolitis with longer hospital stay and higher health care costs. Incidence of a fetus developing a small size for gestational age is about 8%. Fetal growth is regulated by the balance between fetal nutrient demand and maternal placental nutrient supply. Intrauterine growth restriction may be caused by maternal, placental, or fetal factors. Nearly one-third of IUGRs are due to genetic causes, and two-thirds are related to the fetal environment. In the developing world, IUGR is likely to be a consequence of poor maternal nutritional status prior to or during pregnancy.

There are two general patterns of growth abnormalities: symmetric and asymmetric. Symmetric growth inhibition arises during the first half of gestation, when fetal growth occurs primarily through cellular division and produces an undersized fetus with fewer cells of normal size. Asymmetric growth inhibition occurs during the second half of gestation and is usually the consequence of an inadequate availability of substrates for fetal metabolism. To prevent the previously mentioned complications of IUGR, it is important to establish markers which can identify pregnancies at risk of IUGR early enough. Recently several studies have highlighted the role of many bio-molecules as markers for IUGR like leptin, adiponectin, endothelin-1, lactate dehydrogenase, s-endoglin, pregnancy associated plasma protein, metastin. Apart from being expensive, laboratories at majority of centers are not equipped with facilities of measurement of these markers. Measurement of maternal serum ferritin has also been used as a predictive marker for increased risk of IUGR in one previous study on a limited number (seventeen) of cases. Ferritin is an intracellular protein consisting of 24 heavy and light sub-units surrounding a core that can store up to 4,500 iron atoms. The two sub-units are highly conserved during evolution, but only the heavy sub-unit has ferroxidase activity. Ferritin is released by infiltrating leukocytes, in response to acute and chronic infection. Ferritin as an acute phase reactant is well known for its intracellular iron sequestration and storage abilities during immune activation. Serum ferritin concentration is positively correlated with the amount of total body iron stores in the absence of inflammation. Serum ferritin is considered a valuable bio-marker for body iron status in healthy subjects.Iron deficiency has its known deleterious effect in pregnancy but iron loading may be associated with oxidative damage to cells and tissues. It has been shown in various studies that lower level of transferritin receptor expression in placenta is associated with preeclampsia and IUGR. This can lead to decrease extraction of iron by placenta from maternal serum leading to increase maternal serum ferritin. This fetal iron deficiency leads to increase in fetal corticotropins and fetal cortisol, causing inhibition of fetal growth.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Older than 20 years of age
  • Pregnant with singleton intrauterine pregnancy
  • 30th-32nd weeks of gestation

排除标准

  • Patients with a history of anemia due to any causes.
  • Patients with history of iron supplementation, Clinical and/or laboratory evidence of hepatic, renal, hematologic, cardiovascular abnormalities.
  • History of acid-peptic disorders, esophagitis, or hiatal hernia.
  • Family history of thalassemia, sickle cell anemia, or malabsorption syndrome.
  • Antepartum hemorrhage.
  • Allergies to milk proteins / hypersensitivity to iron preparations.
  • Patients with acute infection, positive CRP, raised TLC count.
  • Congenital malformation and fetuses with chromosomal or genetic syndrome.
  • Recent blood transfusion.
  • Refusal to participate in the study.
  • Placental abnormalities like velamentous insertion.
  • Multiple pregnancies.
  • Smoking during pregnancy
  • Preterm births.

结局指标

主要结局

maternal serum ferritin (microg/L)

时间窗: 2 months

Ferritin values will be estimated by immunometric testing for quantitative determination in human serum at Olympus analyzers using the Olympus ferritin reagent. Reference ranges from 10.00 to 30.00 microgram/L

Fetal weight (gm)

时间窗: 5 minutes

birth weight less than 10th percentile will be adjusted for small for gestational age

次要结局

  • Maternal hemoglobin (g/L)(2 months)
  • Maternal hematocrit (x10^12/L)(2 months)
  • Apgar score(5 minutes)
  • Maternal total leucocytic count (x10^9/L)(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shaimaa Mahmoud salem

principal investigator

Ain Shams Maternity Hospital

研究点 (2)

Loading locations...

相似试验